



---

**Abstract**

2 messages

---

**alice** <alice\_m\_moore@hotmail.com>  
To: "2016mcsc@gmail.com" <2016mcsc@gmail.com>

Thu, Sep 29, 2016 at 2:57 PM

**LCZ696 Compassionate Use Programme***Alice Moore, Lisa Buttigieg, Sara Xuereb, Robert Xuereb**Mater Dei Hospital Malta*

**Background:** LCZ696 is a combination drug consisting of valsartan and sacubitril. The trial PARADIGM-HF has shown a 20% risk reduction in death from CV cause and 21% HF hospitalization risk reduction when LCZ696 was compared to enalapril.

**Aim:** An audit to assess the effect of LCZ696 in HF patients included in the Compassionate Use Programme at Mater Dei Hospital.

**Method:** Patients that attend the HF Clinic were selected between October 2015 and May 2016. Inclusion criteria included: Age>18; NYHA Class II-IV; LVEF<35%; at least one hospitalization for HF within the last 12 months; ACE-inhibitor or ARB therapy with stable dose for prior 4 weeks.

**Results:** 21 patients were included: 16 males, 5 females. Average age was 56.8. 81% of patients reached target dose within an average time of 37.5 days. 57% had a significant decline in NTproBNP levels. Since starting LCZ696, only 2 patients required hospitalization for HF exacerbation. Loop diuretics were stopped in 15% of patients and dose was reduced in 45%. 2 patients discontinued therapy because of hyperkalaemia and acute renal failure respectively.

**Conclusion:** The introduction of LCZ696 had a positive effect on HF management with reduction in NTproBNP levels, number of hospitalizations and reduced need of loop diuretics.

---

**Malta Cardiac Society Conference** <2016mcsc@gmail.com>  
To: alice <alice\_m\_moore@hotmail.com>

Thu, Sep 29, 2016 at 7:14 PM

Dear Author

On behalf of the organizing committee, I would like to thank you for your abstract submission. We will be in touch after the submission deadline.

Thank You

Best Regards

[Quoted text hidden]

--

Dr Mark Abela MD (Melit) MRCP (UK) MRCP (London) MSc (Edin)  
Cardiology Higher Specialist Trainee  
Department of Cardiology, Mater Dei Hospital, Malta  
Email: [markabela88@gmail.com](mailto:markabela88@gmail.com)

On Behalf of the Maltese Cardiac Society Conference 2016 Organizing Committee